Search

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.

BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US

Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.

Generalized Pustular Psoriasis: Impact Beyond the Skin

Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.

Creating an Inclusive Workplace for Employees with Disabilities

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing

New Documentary Highlights Ranch’s Commitment to Cattle Health

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Partnering for Innovation in Animal Health

Video with Erik Haaksma and Megan Grether describing how partnering is an essential component of innovation at Boehringer Ingelheim Animal Health.

Boehringer Ingelheim Acquires AMAL Therapeutics

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Click here to read more on the possible signs of diabetes in your feline friends, including how to identify and prevent potential symptoms and risks.

Partnering Interests

Search

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US

The power of patient advocacy in cancer care

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US

Generalized Pustular Psoriasis: Impact Beyond the Skin

Creating an Inclusive Workplace for Employees with Disabilities

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

FDA approves additional formulation of biosimilar

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

New Documentary Highlights Ranch’s Commitment to Cattle Health

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Partnering for Innovation in Animal Health

Boehringer Ingelheim Acquires AMAL Therapeutics

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Partnering Interests

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US

The power of patient advocacy in cancer care

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US

Generalized Pustular Psoriasis: Impact Beyond the Skin

Creating an Inclusive Workplace for Employees with Disabilities

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

FDA approves additional formulation of biosimilar

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing

New Documentary Highlights Ranch’s Commitment to Cattle Health

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Partnering for Innovation in Animal Health

Boehringer Ingelheim Acquires AMAL Therapeutics

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Partnering Interests